Table 1 Patient characteristics
Characteristics | Study cohort (N = 34) |
|---|---|
Age (years), median (IQR) | 13.5 (12–18) |
Adolescents (12–17 years), n (%) | 25 (73.5) |
Young adults (18–22 years), n (%) | 9 (26.5) |
Male, n (%) | 20 (59) |
Race/Ethnicity, n (%) | |
African American | 31 (91) |
Hispanics or Latino | 3 (9) |
Genotype, n (%) | |
HbSS | 29 (85.3) |
HbSC | 3 (8.8) |
HbSB0 | 2 (5.9) |
Indication for hydroxyurea, n (%) | |
Recurrent pain | 18 (52.9) |
Recurrent ACS | 2 (5.9) |
Recurrent pain and ACS | 9 (26.5) |
Othersa | 5 (14.7) |
Hydroxyurea dose (mg/kg/dose), median (IQR) | 33.8 (28.9–35) |
Hydroxyurea duration (months), median (IQR) | 70.5 (30–100) |
Hydroxyurea duration - steady dose (months), median (IQR) | 14 (7–22) |
Number of SCD-related hospitalizations in 1 year, n (%) | |
0 | 14 (41.2) |
1–3 | 11 (32.3) |
4 or more | 9 (26.5) |
Laboratory markers, median (IQR) | |
Fetal haemoglobin (%) | 15.1 (9.4–30.7) |
Haemoglobin (g/dl) | 9.4 (8.5–10) |
Red blood cells count (106/ml) | 2.6 (2.4–3.1) |
Mean corpuscular volume (fl) | 101.1 (92.8–110.9) |
Reticulocyte count (%) | 8.7 (3.7–15) |
White blood cells count (103/ml) | 6.6 (4.6–8.8) |
Absolute neutrophil count (103/ml) | 3572 (2318–5282) |
Platelet count (103/ml) | 340 (204–448) |